Human Bladder Carcinoma is Dominated by T-Regulatory Cells and Th1 Inhibitory Cytokines-Reference-Cited by-同舟云学术

Human Bladder Carcinoma is Dominated by T-Regulatory Cells and Th1 Inhibitory Cytokines

Published:2007-01 Issue:1 Volume:177 Page:353-358
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Loskog Angelica¹,Ninalga Christina¹,Paul-Wetterberg Gabriella¹,de la Torre Manuel²,Malmström Per-Uno²,Tötterman Thomas H.¹

Affiliation:

1. Clinical Immunology Division, Rudbeck Laboratory C11/Uppsala University, Uppsala, Sweden

2. Department of Urology, Akademiska Sjukhuset/University Hospital, Uppsala, Sweden

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference15 articles.

1. The immunotherapy of prostate and bladder cancer;Totterman;BJU Int,2005

2. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells;Couderc;Cancer Gene Ther,1998

3. Human cancer gene therapy with cytokine gene-modified cells;Wysocki;Expert Opin Biol Ther,2004

4. CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer;Ninalga;J Immunother,2005

5. Human CD4+CD25+ regulatory T cells;Baecher-Allan;Semin Immunol,2004

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of epithelial-related artificial neural network prognostic models for the prediction of bladder cancer prognosis through comprehensive analysis of single-cell and bulk RNA sequencing;Heliyon;2024-08

2. MALT1 inhibition suppresses antigen-specific T cell responses;Cellular Immunology;2024-03

3. Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma;Cancer Research Communications;2024-02-26

4. Matched Analysis of Detailed Peripheral Blood and Tumor Immune Microenvironment Profiles in Bladder Cancer;Epigenomics;2024-01

5. OncoTherad® (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette–Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Crosstalk among T-Cell CX3CR1, Immune Checkpoints, and the Toll-Like Receptor 4 Signaling Pathway;International Journal of Molecular Sciences;2023-12-15